RxDoctor Payments Data

Adriana Dunay, PA

Physician Assistant · Canonsburg, PANPI 1194359612

Payments from drug & device makers

$4,233in general payments, 2019–2025

Across 135 payments — averaging $31.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cequr Corporation$2K
  • Novo Nordisk$515
  • Dexcom, Inc.$372
  • Bayer$306
  • Lilly USA, LLC$245
  • Medtronic$197
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,233100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,233 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$30,968
Medicare patients
186
Services billed
337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide272$397,708
TrulicityDulaglutide241$331,868
JardianceEmpagliflozin198$247,594
Tresiba Flextouch U-100Insulin Degludec84$53,816
MounjaroTirzepatide33$51,387
FarxigaDapagliflozin Propanediol60$46,626
Tresiba Flextouch U-200Insulin Degludec23$41,162
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$35,419
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/721$34,413
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog85$33,989
Victoza 3-PakLiraglutide24$28,791
Lantus SolostarInsulin Glargine,hum.Rec.Anlog214$27,009
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$24,408
Novolog FlexpenInsulin Aspart80$24,084
Fiasp FlextouchInsulin Aspart (Niacinamide)20$23,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$515$423,756305 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$245$396,230321 claims
Boehringer IngelheimJardiance, Tradjenta$73$269,787223 claims
AstraZenecaFarxiga$68$46,62660 claims
Johnson & JohnsonInvokana$43$11,79313 claims
AbbVieSynthroid$73$3,05666 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$112$2,742250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Canonsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →